| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD9876 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.023 | 0.7 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.7 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | -0.015 | 0.7 |
| mRNA | KIN001-266 | GDSC1000 | pan-cancer | AAC | 0.016 | 0.7 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | 0.015 | 0.7 |
| mRNA | A-804598 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.7 |